gmp-verlag.de
 
 
Shopping cart
Your shopping cart is empty

Show shopping cart...
 
 

Image

 
 
Contact us

Maas & Peither AG
Karlstrasse 2
79650 Schopfheim, Germany

Phone +49 (0)7622 666 86-70
Fax     +49 (0)7622 666 86-77
E-mail service@gmp-publishing.com

 

Maas & Peither America, Inc.
1060 First Avenue, Suite 400
King of Prussia, PA 19406, USA

Phone +1 (610) 768-8028
Fax     +1 (610) 337-9548
E-mail service@gmp-publishing.com

URL www.gmp-publishing.com

 

International Publications

Risk-Based Compliance Handbook
€ 181.00
net
€ 193.67
  7% VAT included
US$
259.00
This book covers all stages of the drug lifecycle from R&D, to the clinical phases, the launch and pharmacovigilance stages, and the discontinuation step.
Edition: 2008
186 Pages
ISBN: 1-933722-24-X
   x
The application of risk management to the processes within the healthcare industry is not just good practice, but an essential must do for any competitive and compliant enterprise. Whereas the ICH Q9 guideline “Quality Risk Management” describes the fundamental concepts, additional information is needed to further describe how risk management can and should be applied to the regulated healthcare environment. This publication puts into context the various risk assessment methodologies with the business needs at the various stages of the life cycle. The emphasis is on implementing and achieving competitive compliance through the application of risk management.

In this book you will find crucial information on:
- An introduction to the various risk methodologies and their terminology
- Selecting the best method for a particular stage in the drug lifecycle
- Building risk management into the Quality Management System
- Many practical examples from real industry applications, including PAT
- The application of risk management for optimising the benefit/risk ratios

This book has been written by several authors who are experts in their field. It covers all stages of the drug lifecycle from R&D, to the clinical phases, the launch and pharmacovigilance stages, and the discontinuation step. It is written for the practitioner in the operational part of the organisation, who wishes to select from practical examples, and it will be equally of interest to those working in quality assurance / compliance, who wish to learn more about implementing risk management as a quality concept.

Table of Contents:
Chapter 1: Introduction
Chapter 2: Compliance and the Lifecycle Concept
Chapter 3: Impact on Quality Management Systems
Chapter 4: Risk-Based Approach to Compliance
Chapter 5: Implementing Process Analytical Technology: The Challenges and Pitfalls of Applying a Science and Rick-Based Approach in Research and Manufacturing
Chapter 6: The Applicability of ICH Q9
Chapter 7: Benefit Risk Assessment During R&D
Chapter 8: The Cost of Quality
Chapter 9: How to Implement?
Chapter 10: Documented Evidence
Chapter 11: Quo Vadis?
Index
Schmitt Siegfried, PhD is a Member of the Royal Society of Chemistry, Chartered Chemist and Chartered Scientist. Having worked in industry and in the consulting business he has more than 18 years experience in the healthcare industry. In 2007 he joined PAREXEL Consulting in the UK as Principal Consultant in the Strategic Compliance and Operational Performance Excellence team. He regularly publishes articles on scientific and business subjects, and has written several books. He speaks at international conferences and industry meetings on a variety of topics, especially covering the integration of modern business methodologies with compliance. He is the author of The Manager`s Validation Handbook: Strategic Tools for Applying Six Sigma to Validation Compliance and Understanding Active Pharmaceutical Ingredients.

Yvonne Lis, PhD is an experienced health outcomes researcher with more than 25 years in the industry. Her clinical research in London teaching hospitals was marked by several publications in peer reviewed journals and her subsequent commercial experience has focused on epidemiology, pharmacoepidemiology, pharmaco-economics and risk management. Most recently she has been working with the international pharmaceutical industry on the application of outcomes research methodologies to address the emerging market access challenges faced by products in Phase II/Phase III development. She regularly contributes to International Society Pharmacoeconomics and Outcomes Research (ISPOR) working parties including: Good Research Practices for Registries; Using “Real World” Data in Coverage and Reimbursement; Good Research Practices for Drug Cost, Economic Evaluation Research and Use in Health Care Policy. A Fellow of the Royal Society of Medicine, she has also been a Senior Research Fellow at the Department of Medicine and Epidemiology, McGill University, Canada.

Michael Carter is an experienced health outcomes researcher having provided consultancy support to the international pharmaceutical industry for more than 15 years. His considerable previous experience in product development and business strategy enable him to provide a clear focus on ensuring that the science being performed is clearly aligned with the achievement of key business objectives. He is a regular speaker at industry conferences and has recently served as a non-executive director of a UK Primary Care Trust.

Jan Olsen CEO Clarmon Corporation, is an experienced senior manager in IT, mechanical engineering and compliance management. He has over 17 years of IT and compliance management experience from a long list of listed companies. He has very strong experience in both compliance tool development and IT implementation, having worked as MD, CTO and Executive Director on several successful technology start-ups. He also served as general manager of a largescale offshore facility in Romania with a 350+ engineering staff delivering engineering solutions to a number of regulated companies. Jan holds a B.Sc. in Business and an M.Sc. in Management.

Jennifer Thompson (previously Methfessel) is an IT and computer systems compliance expert with more than 15 years of experience across a wide range healthcare companies, system suppliers and service providers in the UK, Europe and USA. She joined ABB eight years ago where she is a Principal Consultant in Validation and Compliance Consultancy and works closely with the ABB ProcessAnalyticalTechnology Centre of Excellence. She has a special interest in PAT as she has a Ph.D. in physics, specialising in spectroscopic techniques. She is a Member of the Institute of Physics, chartered physicist and has a Diploma in Business Management. An active member of ISPE and GAMP, she regularly writes articles and presents at international conferences. Jennifer particularly enjoys applying her business knowledge and scientific training in working with clients to develop and implement risk-based strategies for PAT, business systems and IT and computerised systems compliance, validation and qualification.
PDA/DHI Publication
Recommendations
Risk Management (Download)
A Process Approach to Pharmaceutical Quality Systems
Risk-Based Compliance Handbook